Could a cancer drug help cure hepatitis b? new trial launches
NCT ID NCT06357806
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether adding a PD-1 antibody (sintilimab) and pegylated interferon to standard antiviral therapy can help people with chronic hepatitis B lose the hepatitis B surface antigen (HBsAg), a key step toward a functional cure. The trial will enroll 45 adults who have been on antivirals for at least a year and have low but detectable HBsAg levels. Researchers will monitor safety and how many participants clear HBsAg at 24 and 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sintilimab (PD-1 antibody) combined with pegylated interferon-α2b
- What this could lead to
- If successful, this combination could help more people with chronic hepatitis B achieve a functional cure, meaning the virus is suppressed without lifelong medication.
- What could go wrong
- This is a small, early pilot study with only 45 participants, so results may not apply broadly. The treatment can cause immune-related side effects, and it is not yet known if it will work better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Fifth Medical Center, Chinese PLA General Hospital
Beijing, Beijing Municipality, 100039, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data
- Can fatty liver and hepatitis b together harm kidneys? a study digs into the data